Sweden's Vitrolife Q2 net income rises, helped by one-time gains
Sweden's Vitrolife Q2 net income rises, helped by one-time gains
Overview
Sweden reproductive health device maker's Q2 revenue fell 1% in local currencies, down 2% in SEK
Q2 adjusted EBITDA margin rose to 34.4%, helped by one-time effects and currency gains
Net income and EPS increased yr/yr despite lower revenue
Outlook
Vitrolife did not provide specific guidance or outlook for future periods in the press release
Result Drivers
ONE-TIME EFFECTS - Profitability was positively affected by a VAT accrual reversal and currency revaluation in operating expenses
PRODUCT MIX - Modest growth in consumables and technologies offset by decline in genetics sales
EXITED BUSINESSES - Organic growth was 1% in local currencies excluding exited NACE and GDPX product lines
Company press release: ID:nMFN97VFfD
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| SEK 857 mln |
|
Q2 EPS |
| SEK 0.95 |
|
Q2 Net Income |
| SEK 129 mln |
|
Q2 EBITDA |
| SEK 295 mln |
|
Q2 EBITDA Margin |
| 34.40% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Vitrolife AB is SEK131.00, about 50.1% above its July 15 closing price of SEK87.30
The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 22 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)